The Revenue Layer · Insights

Insights

Writing on AI, modernization, and enterprise growth, drawn from operating inside the most regulated, complex environments in technology, financial services, healthcare, and the public sector.

The commercial question

Capability gets attention.
Commitment moves the deal.

Executive Framework · July 2026

The Revenue System for Enterprise AI

How CROs and sales leaders convert complex buying decisions into production growth.

AI has not replaced the fundamentals of complex enterprise selling. It has shortened the window in which sponsorship, ownership, funded alignment, and success criteria must become visible. Capability creates attention fast; commitment is what moves the deal. This paper gives CROs and sales leaders an operating response: forecast on resolved customer decisions rather than demonstrations, design coverage around the buying group, and move scarce technical and executive resources toward the opportunities where commitment is forming.

  • Six decisions inside every AI sale: fit, return, form, governance, build or buy, placement
  • Forecast on resolved customer decisions, not demonstrations
  • Coverage designed around the buying group, not titles
  • Forward deployed resources aimed at a named uncertainty
  • A ninety-day CRO operating test
The successor question

Where should the application run?
Now: where should intelligence run?

Executive Framework · July 2026

The Inference Placement Framework

An executive framework for placing AI reasoning across the enterprise.

For three decades, enterprise architecture answered one question: where should the application run? AI adds a second, and it is harder. This framework answers it at the level of each consequential inference step, not the model and not the platform, so the answer follows the decision the business needs to make. Score that decision on nine dimensions, place it deliberately across four environments, and govern the whole portfolio through one gateway.

  • The inference step as the unit of placement
  • Nine executive questions for every decision
  • A four-position spectrum, commercial cloud to edge
  • One gateway governing the whole portfolio
  • A thirty-minute exercise to map your gaps
⌒
Growth & Commercialization

AI Doesn't Change How Deals Get Done

The fundamentals still decide everything: sponsorship, ownership, alignment to a funded initiative. What's different is when those have to show up, and how fast.

View on LinkedIn →
▲
AI & Modernization

AI Is Accelerating Modernization, Not Waiting for It

One of the biggest misconceptions in enterprise AI is that companies must fully modernize before they can operationalize it at scale. The enterprises moving fastest are doing the opposite.

View on LinkedIn →
⬡
AI & Enterprise Value

Turning AI Investment Into Business Value

The challenge is no longer adopting AI. It is turning AI investment into measurable business value at scale.

⟡
AI & Modernization

The Future Is Not Plug-and-Play. Partner-and-Build.

Legacy systems are often the gating factor to scalable cloud and AI transformation. Translation alone is not transformation. Modernization still requires governed data and disciplined execution.

◆
Healthcare & Life Sciences

Not Discovering the Next Cure. Delivering the Ones We Have.

One of the most important opportunities for AI in healthcare may not be discovering the next cure. It may be making sure the cures we already have actually reach patients.

View on LinkedIn →
◉
Healthcare & Life Sciences

AI in Life Sciences Is Entering a Different Phase

The Novo Nordisk and AWS partnership caught my attention, not simply because of the technology, but because of what it signals. AI is moving deeper into how life sciences companies actually operate. Their work connects genomic, imaging, and clinical data so insights from early research can help inform clinical trial design, and they are already reporting reduced clinical documentation time and AI use by more than 25,000 employees.

View on LinkedIn →
⬢
Healthcare & Life Sciences

In Clinical Development, the Collapse of Waiting Time

The FDA is moving toward real-time clinical trials, where selected safety and efficacy signals can be reviewed as a study progresses rather than after months of data preparation, reconciliation, and submission. That changes more than regulatory workflow. It changes the value of the entire clinical-development infrastructure.

View on LinkedIn →
◇
Healthcare & Life Sciences

Health Context Is Not a Destination. It Is Ambient.

OpenAI's Health launch lets users connect Apple Health and supported medical records, so ChatGPT can draw on medications, labs, recent visits, sleep, and activity in context. Among early users with access, more than 70% of health-related conversations happened outside the dedicated Health experience.

View on LinkedIn →
◈
Healthcare & Life Sciences

AI May Become the Catalyst for Healthcare Modernization

Legacy infrastructure and fragmented data have made large-scale transformation difficult for years. AI is starting to change that dynamic, by compressing modernization timelines, not just adding a new layer.

◎
Healthcare & Life Sciences

The Next Chapter of AI in Healthcare & Life Sciences

Healthcare and life sciences are entering a new phase, where connected operations, trusted data, and AI can improve how regulated organizations run, respond, and scale.

Get in touch

Let's build what's next.

Open to fractional CRO engagements, advisory work, and board conversations with leaders in enterprise AI, technology, and regulated industries.